Lupin, Fuji sign agreement to commercialise Nextstellis in Vietnam, Philippines

hanuman

Active member
Acquisition.jpg


Lupin announced that it has signed a license and supply agreement with OLIC, Thailand, a subsidiary of the Japanese pharmaceutical company Fuji Pharma, for marketing Nextstellis (drospirenone and estetrol tablets) in Vietnam and the Philippines.

Nextstellis is a novel combination medication comprising drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.

Fuji is a Tokyo Stock Exchange (TSE) listed, Japan‐based pharmaceutical company mainly engaged in the manufacture and sale of prescription-based pharmaceutical products. Fuji focuses on the field of women’s health care with a wide variety of new and generic drugs for women’s specific diseases such as infertility, dysmenorrhea, endometriosis, contraception, and menopausal disorders.

The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock